Keywords: Apexigen, Gansu Duyiwei, APX004, Cancer, Angiogenic diseases, China

Apexigen licenses MAb to Gansu Duyiwei for China

Article | 12 March 2012

Privately-held US biopharma firm Apexigen has entered into a collaboration to grant an exclusive license to Gansu Duyiwei Biological Pharmaceutical ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Apexigen

Gansu Duyiwei

Go to company listing